Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Jun 15, 2011 (Vol. 31, No. 12)

Center for Scientific Review

URL:cms.csr.nih.gov
  • Great organization, resources for reviewers and applicants
  • None

Just as young investigators in academia must learn how to think critically and plan experiments, they must also learn to convince others that their work is worth funding. That’s right, the dreaded “G” word: grants. The grant proposal process in general can sometimes seem like a black box, so in an effort to de-mystify it, the Center for Scientific Review of the National Institutes of Health provides an excellent website. The site includes resources such as links to YouTube videos about the review process, answers to frequently asked questions, and an “insider’s guide to peer review” for applicants. The website isn’t only geared toward the applicants, though. There are also a number of resources for reviewers, including reviewer guidelines and an orientation to the whole process. Nicely organized and full of helpful information, this site is a must for any investigator looking for funding through the NIH.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »